HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PEN
Penumbra, Inc.
PEN's fundamentals are mixed, but it looks cheap: trading at 81x earnings, about a third of its usual 225x. Analysts expect strong earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PEN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Strong |
PEN's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 55x | $321 | — |
| Cheap | 76x | $300 | -6.4% |
| Current | 81x | $321 | — |
| Fair | 222x | $883 | +175% |
| Expensive | 648x | $2,574 | +702% |
Historical ranges are pointers, not guarantees.
PEN's PE is in its cheap range at 81x. If earnings grow as analysts expect, today's price would be 55x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PEN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
PEN has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.82 | +47% |
| Q3 2026 | $3.97 | -5.5% |
| Q2 2026 | $4.07 | +7.7% |
| Q1 2026 | $4.34 | +302% |
| Q4 2025 | $4.52 | +1156% |
| Q3 2025 | $4.20 | +388% |
| Q2 2025 | $3.78 | +1012% |
| Q1 2025 | $1.08 | -54% |
| Q4 2024 | $0.36 | -84% |
PEN has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PEN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $410.1M | +16% |
| Q2 2026 | $390M | +15% |
| Q1 2026 | $374.8M | +16% |
| Q4 2025 | $385.4M | +22% |
| Q3 2025 | $354.7M | +18% |
| Q2 2025 | $339.5M | +13% |
| Q1 2025 | $324.1M | +16% |
| Q4 2024 | $315.5M | +11% |
PEN's revenue has grown year over year every quarter since late 2020: $410M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 12% | -1.4 points |
| Q2 2026 | 11% | -1.5 points |
| Q1 2026 | 10% | -2.3 points |
| Q4 2025 | 15% | +1.8 points |
| Q3 2025 | 14% | +2 points |
| Q2 2025 | 12% | +39 points |
| Q1 2025 | 12% | +8.1 points |
| Q4 2024 | 14% | +1.3 points |
PEN has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PEN on cash flow, with more consistent year-over-year improvement.
PEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26.4M | -37% |
| Q2 2026 | $32.5M | +11% |
| Q1 2026 | $73.3M | +106% |
| Q4 2025 | $68.1M | +49% |
| Q3 2025 | $42M | -18% |
| Q2 2025 | $29.4M | +62% |
| Q1 2025 | $35.5M | +9.3% |
| Q4 2024 | $45.7M | +40% |
PEN generated $200M in free cash flow over the past year, up 31% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PEN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +48.2K shares |
| 1 year | +0.8% | +318K shares |
| 3 years | +1% | +400K shares |
| 5 years | +5.3% | +2M shares |
| Available history | +9.1% | +3.3M shares |
PEN has 40M diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q4 2024 | $1,000 |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.2x | Net Cash |
| Q2 2026 | -1.0x | Net Cash |
| Q1 2026 | -1.2x | Net Cash |
| Q4 2025 | -0.9x | Net Cash |
| Q3 2025 | -1.7x | Net Cash |
| Q2 2025 | -2.4x | Net Cash |
| Q1 2025 | -6.4x | Net Cash |
| Q4 2024 | -9.8x | Net Cash |
PEN has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.7 | Neutral |
| Stochastic | 27.1 | Neutral |
PEN's weekly RSI is 51 (neutral) and its Stochastic is 27 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PEN PE vs Healthcare Sector
| Metric | PEN | Sector median | Relative |
|---|---|---|---|
| PE | 81x | 26x | 213% above |
| PE % | 26 | 29 | 3 pts below |
PEN is trading at 81x earnings, a 213% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $320.0 | 0.2% above |
| 20 week MA | $320.6 | 0.1% above |
| 50 week MA | $325.6 | 1.5% below |
| 100 week MA | $294.7 | 8.8% above |
| 200 week MA | $267.7 | 20% above |
PEN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $164.1 | $187.4 | +14% |
| 2021 | $187.4 | $275.6 | +47% |
| 2022 | $275.6 | $219.6 | -20% |
| 2023 | $219.6 | $251.5 | +15% |
| 2024 | $251.5 | $239.9 | -4.6% |
| 2025 | $239.9 | $317.0 | +32% |
| 2026 YTD | $317.0 | $320.8 | +1.2% |
PEN has the edge over HIMS on returns for 2026, with the stronger performance.